IDEAYA Biosciences, Inc.
IDYA
$40.17
$0.220.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 234.13M | 225.27M | 218.71M | 214.83M | 7.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 234.13M | 225.27M | 218.71M | 214.83M | 7.00M |
| Cost of Revenue | 274.78M | 272.45M | 247.61M | 301.19M | 275.35M |
| Gross Profit | -40.65M | -47.18M | -28.90M | -86.36M | -268.35M |
| SG&A Expenses | 77.07M | 69.19M | 63.32M | 55.43M | 48.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 451.08M | 408.74M | 378.02M | 423.72M | 391.23M |
| Operating Income | -216.95M | -183.47M | -159.31M | -208.88M | -384.23M |
| Income Before Tax | -175.02M | -140.06M | -113.70M | -160.74M | -331.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -175.02 | -140.06 | -113.70 | -160.74 | -331.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -175.02M | -140.06M | -113.70M | -160.74M | -331.80M |
| EBIT | -216.95M | -183.47M | -159.31M | -208.88M | -384.23M |
| EBITDA | -214.20M | -180.68M | -156.61M | -206.33M | -381.76M |
| EPS Basic | -1.93 | -1.58 | -1.29 | -1.84 | -3.79 |
| Normalized Basic EPS | -1.27 | -1.06 | -0.87 | -1.31 | -2.53 |
| EPS Diluted | -1.95 | -1.60 | -1.31 | -1.85 | -3.79 |
| Normalized Diluted EPS | -1.28 | -1.07 | -0.89 | -1.33 | -2.53 |
| Average Basic Shares Outstanding | 357.87M | 354.28M | 353.94M | 352.70M | 350.36M |
| Average Diluted Shares Outstanding | 359.03M | 355.45M | 355.10M | 353.86M | 350.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |